ARTICLE | Company News

Threshold cancer news

January 4, 2016 8:00 AM UTC

Threshold will reduce headcount by about 66% to 20-25 to focus resources on two ongoing Phase II trials of tarloxotinib ( TH-4000) to treat non-small cell lung cancer (NSCLC) and squamous cell carcinomas of the head and neck or skin, respectively. Tarloxotinib is a hypoxia-activated irreversible EGFR and EGFR2 ( HER2; ErbB2; neu) tyrosine kinase inhibitor. Threshold has exclusive, worldwide rights to the compound from the University of Auckland (Auckland, New Zealand) under a 2014 deal. ...